Brain Cancer Trial, Recruiting NCT07251868 Sponsor: Peking University Cancer Hospital & Institute Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT07251868
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old, and there is no restriction on gender
  • You are able to understand what the study involves and are willing to sign a consent form — or, if you have difficulty understanding or communicating, a legal guardian can sign on your behalf
  • Your full medical records (including your breast cancer diagnosis, brain metastasis diagnosis, and treatment history) are available at one of the study's participating hospitals
  • You have been diagnosed with breast cancer through a tissue or cell sample test, with the report issued by a qualified major hospital or the study's designated pathology centre
  • You have been diagnosed with breast cancer that has spread to the brain, confirmed by a brain scan (MRI or CT with contrast dye), surgery, or biopsy
  • There are no restrictions on how many brain tumours you have, their size, whether the cancer has spread to the lining of the brain, or whether you have symptoms like headaches or limb weakness
  • You have previously been treated with a drug called Sacituzumab Govitecan (SG), and there is a clear medication record — it does not matter which line of treatment it was, what dose you received, or how many cycles you completed
  • You may currently be on SG treatment, have finished it, or have stopped it for any reason
  • Your general health is currently stable and you do not have any of the following uncontrolled serious conditions: a severe infection (such as blood poisoning or severe pneumonia), seizures in the past 3 months, or severe failure of the heart, liver, or kidneys (confirm with trial site)
  • You (or your guardian) are able to attend follow-up appointments or be contacted by phone or electronic records during the study period

Who may not be able to join:

  • You have or have had another separate cancer (other than breast cancer) that was still active at any point in the last 5 years
  • You are unable to give consent or take part in follow-up due to a mental health condition or cognitive impairment, and you do not have a qualified guardian who can assist
  • You are currently taking part in another type of interventional clinical trial (such as a randomised controlled trial) that could affect this study's results
  • The study doctor decides there is another reason that could affect your safety or the quality of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University Cancer Hospital & Institute
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Real world progression free survival (rwPFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov